Immediate Impact

3 by Nobel laureates 8 from Science/Nature 95 standout
Sub-graph 1 of 21

Citing Papers

Cancer biomarkers: Emerging trends and clinical implications for personalized treatment
2024 Standout
Fluorescent Probes for Disease Diagnosis
2024 Standout
4 intermediate papers

Works of R. Asola being referenced

Adjuvant Capecitabine, Docetaxel, Cyclophosphamide, and Epirubicin for Early Breast Cancer: Final Analysis of the Randomized FinXX Trial
2011
Fluorouracil, Epirubicin, and Cyclophosphamide With Either Docetaxel or Vinorelbine, With or Without Trastuzumab, As Adjuvant Treatments of Breast Cancer: Final Results of the FinHer Trial
2009
and 1 more

Author Peers

Author Last Decade Papers Cites
R. Asola 516 277 208 16 683
D F Hayes 451 322 152 11 743
L. D. Ziegler 520 321 174 18 739
Melissa Brammer 574 146 346 36 732
G. Piot 459 157 143 21 682
Rémy Largillier 461 309 139 31 702
W. E. C. Allt 196 235 160 11 674
B. Lisboa 465 366 95 23 770
A. Galid 507 206 164 26 734
Robert W. Frelick 497 417 158 20 831
R. Kokko 644 406 160 22 819

All Works

Loading papers...

Rankless by CCL
2026